GLPwatch

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03693430 · Completed

Last updated 2026-05-28

This clinical trial is testing how well the medication semaglutide works to help people with overweight or obesity lose weight over a two-year period.

Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 304 people
Who can join all sexes
Timeline Started 2018-10 · est. completion 2021-03
Where 41 sites · Canada, Hungary, Italy, Spain, United States

What this study is testing ClinicalTrials.gov NCT03693430 ↗

Description as written by the study sponsor.

This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine. In addition to taking the medicine, participants will also have talks with study staff about healthy food choices, how the participant can be more physically active and what participants can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment the participant gets is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 2 years. The participants will have 19 clinic visits and 15 phone calls with the study doctor.

Treatments tested

Main thing measuredPercentage Change From Baseline (Week 0) to Week 104 in Body Weight
SponsorNovo Nordisk A/S
Conditions studiedOverweight, Obesity
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03693430 ↗